NOVEL SIGMA RECEPTOR LIGANDS AND METHODS OF MODULATING CELLULAR PROTEIN HOMEOSTASIS USING SAME
申请人:Drexel University
公开号:US20150166472A1
公开(公告)日:2015-06-18
The present invention includes compounds useful in preventing, treating or ameliorating Sigma-related disorders or diseases. The compounds of the invention can modulate cellular protein homeostasis, which includes: translation initiation, folding, processing, transport, and degradation (including ubiquitin selective autophagy) of proteins. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound, further comprising administering an effective amount of a compound that inhibits the ubiquitin proteasome system (UPS) and/or autophagic survival pathways.
US9388126B2
申请人:——
公开号:US9388126B2
公开(公告)日:2016-07-12
[EN] METHODS OF MODULATING LEVELS OF IL-6 AND PD-L1<br/>[FR] MÉTHODES DE MODULATION DE NIVEAUX D'IL-6 ET DE PD-L1
申请人:UNIV DREXEL
公开号:WO2017106312A1
公开(公告)日:2017-06-22
Embodiments described herein provide methods of treating various diseases or disorders using Sigma1 modulating compounds alone or in combination with other therapeutic agents.
Improved Model of Lanosterol 14α-Demethylase by Ligand-Supported Homology Modeling: Validation by Virtual Screening and Azole Optimization
Lanosterol 14α‐demethylase (CYP51) is an important target for antifungal drugs. An improved three‐dimensional model of CYP51 from Candida albicans (CACYP51) was constructed by ligand‐supported homologymodeling and molecular dynamics simulations. The accuracy of the constructed model was evaluated by its performance in a small‐scale virtual screen. The results show that known CYP51 inhibitors were